ES2611504T3 - Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos - Google Patents

Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos Download PDF

Info

Publication number
ES2611504T3
ES2611504T3 ES13709994.1T ES13709994T ES2611504T3 ES 2611504 T3 ES2611504 T3 ES 2611504T3 ES 13709994 T ES13709994 T ES 13709994T ES 2611504 T3 ES2611504 T3 ES 2611504T3
Authority
ES
Spain
Prior art keywords
analph2
independently
meoh
meo
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13709994.1T
Other languages
English (en)
Spanish (es)
Inventor
Alan Ashworth
Christopher James LORD
Richard James Rowland ELLIOTT
Dan Niculescu-Duvaz
Roderick Porter
Raymond John Boffey
Melanie Jayne BAYFORD
Stuart Firth-Clark
Ashley Nicholas Jarvis
Trevor Robert Perrior
Rebekah Elisabeth KEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Application granted granted Critical
Publication of ES2611504T3 publication Critical patent/ES2611504T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13709994.1T 2012-03-07 2013-03-07 Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos Active ES2611504T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607680P 2012-03-07 2012-03-07
US201261607680P 2012-03-07
PCT/GB2013/050561 WO2013132253A1 (en) 2012-03-07 2013-03-07 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
ES2611504T3 true ES2611504T3 (es) 2017-05-09

Family

ID=47891779

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13709994.1T Active ES2611504T3 (es) 2012-03-07 2013-03-07 Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos

Country Status (13)

Country Link
US (1) US9193689B2 (enExample)
EP (1) EP2822656B1 (enExample)
JP (1) JP6082409B2 (enExample)
KR (1) KR102104144B1 (enExample)
CN (1) CN104302358B (enExample)
AU (1) AU2013229229B2 (enExample)
CA (1) CA2865511A1 (enExample)
DK (1) DK2822656T3 (enExample)
ES (1) ES2611504T3 (enExample)
IN (1) IN2014MN01875A (enExample)
MX (1) MX346147B (enExample)
RU (1) RU2696572C2 (enExample)
WO (1) WO2013132253A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022235492A1 (en) * 2021-05-04 2022-11-10 Board Of Regents, The University Of Texas System Indanone and tetralone-keto or hydroxyl oximes as cancer therapeutics

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
SG11201500732TA (en) * 2012-08-08 2015-02-27 Merck Patent Gmbh (aza-)isoquinolinone derivatives
ES2666729T3 (es) 2013-09-11 2018-05-07 Institute Of Cancer Research: Royal Cancer Hospital (The) Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y su uso terapéutico
ES2969565T3 (es) * 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
CN108289448B (zh) 2015-12-02 2021-10-22 先正达参股股份有限公司 杀微生物的噁二唑衍生物
UY37623A (es) 2017-03-03 2018-09-28 Syngenta Participations Ag Derivados de oxadiazol tiofeno fungicidas
CN110709395A (zh) 2017-06-02 2020-01-17 先正达参股股份有限公司 杀微生物的噁二唑衍生物
WO2018219773A1 (en) 2017-06-02 2018-12-06 Syngenta Participations Ag Fungicidal compositions
WO2019002151A1 (en) 2017-06-28 2019-01-03 Syngenta Participations Ag FUNGICIDE COMPOSITIONS
WO2019011929A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019011923A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019011926A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019011928A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019012011A1 (en) 2017-07-12 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019012003A1 (en) 2017-07-13 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
US12402885B2 (en) 2017-09-23 2025-09-02 Universität Zürich Medical occlusion device
EP3459469A1 (en) 2017-09-23 2019-03-27 Universität Zürich Medical occluder device
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
CN112689631A (zh) 2018-07-16 2021-04-20 先正达农作物保护股份公司 杀微生物的噁二唑衍生物
PL3952995T3 (pl) 2019-04-12 2024-03-11 Riboscience Llc Pochodne bicyklicznych heteroaryli jako inhibitory ekto- pirofosfatazy/fosfodiesterazy nukleotydowej 1
AR118673A1 (es) * 2019-04-18 2021-10-20 Syngenta Crop Protection Ag Procedimiento para la preparación de derivados de oxadiazol microbiocidas
JP7531236B2 (ja) 2019-09-26 2024-08-09 ウニベルシタット チューリッヒ 左心耳閉鎖デバイス
PH12022550960A1 (en) * 2019-10-30 2023-10-09 Digmbio Inc Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient
EP4232925A1 (en) 2020-10-21 2023-08-30 Verint Americas Inc. System and method of automated determination of use of sensitive information and corrective action for improper use
CN117043302A (zh) 2021-03-18 2023-11-10 默克专利有限公司 用于有机电致发光器件的杂芳族化合物
IL314895A (en) * 2022-02-16 2024-10-01 Duke Street Bio Ltd Pharmaceutical compound
CN115572262B (zh) * 2022-10-27 2024-08-27 厦门沃克沃德医药科技有限公司 一种异喹啉衍生物及其制备方法
WO2024238871A1 (en) * 2023-05-18 2024-11-21 Rectify Pharmaceuticals, Inc. Aryl sulfonamide compounds and their use in treating medical conditions
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds
WO2025136936A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Agonists of trem2 activity

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2851458A (en) 1955-06-08 1958-09-09 Burroughs Wellcome Co Diquaternary compounds and the manufacture thereof
US3464563A (en) 1967-02-06 1969-09-02 American Air Filter Co Liquid filter apparatus
US4678500A (en) 1984-06-29 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4942163A (en) 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
EP1020445B1 (en) 1997-10-02 2008-08-13 Eisai R&D Management Co., Ltd. Fused pyridine derivatives
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
BRPI0212726B8 (pt) 2001-09-21 2021-05-25 Bristol Myers Squibb Co compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
NZ537793A (en) * 2002-07-24 2007-05-31 Kyorin Seiyaku Kk 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
CA2500888C (en) * 2002-10-01 2010-07-13 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
KR20050065624A (ko) 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
AU2003301020A1 (en) 2002-12-20 2004-07-22 Sankyo Company, Limited Isoquinolinone derivatives and their use as therapeutic agents
DE602004019518D1 (de) 2003-04-16 2009-04-02 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
WO2005075432A1 (ja) 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用
WO2005113540A1 (ja) 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP5046950B2 (ja) 2004-10-22 2012-10-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼのインヒビター
BRPI0517032A (pt) 2004-12-16 2008-09-30 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
DK1864976T3 (da) 2005-03-31 2012-10-22 Astellas Pharma Inc Propan-1,3-dion-derivat eller salt deraf
KR101431279B1 (ko) 2005-07-29 2014-08-20 리스버로직스 코퍼레이션 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달
AU2006283078A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone Analogs and methods of use thereof
KR101404360B1 (ko) 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 이미다졸 유도체
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
FR2919286A1 (fr) * 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027650A1 (en) 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
BRPI0820504A2 (pt) 2007-11-05 2015-06-16 Novartis Ag Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt
DE102008019838A1 (de) 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
ATE533762T1 (de) 2008-04-22 2011-12-15 Janssen Pharmaceutica Nv Chinolin- oder isochinolinsubstituierte p2x7- antagonisten
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
MX2011008641A (es) 2009-03-06 2011-09-06 Hoffmann La Roche Compuestos heterociclicos antivirales.
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
SI2421533T1 (sl) 2009-04-22 2019-01-31 Resverlogix Corp. Nova protivnetna sredstva
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
MX2012004289A (es) 2009-10-13 2012-06-12 Msd Oss Bv Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina.
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2582680A1 (en) 2010-06-17 2013-04-24 Novartis AG Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
BR112014000792A2 (pt) 2011-07-13 2017-10-31 Novartis Ag compostos de piperidinila para uso como inibidores da tanquirase
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
CA2856759A1 (en) 2011-11-25 2013-05-30 Nerviano Medical Sciences S.R.L. 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors
PT2797921T (pt) 2011-12-31 2017-11-14 Beigene Ltd Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
SG11201404217XA (en) 2012-01-28 2014-08-28 Merck Patent Gmbh Azaheterocyclic compounds
US9174980B2 (en) 2012-01-31 2015-11-03 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
JP6116592B2 (ja) 2012-02-09 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｔａｎｋおよびｐａｒｐのインヒビターとしてのテトラヒドロ−キナゾリノン誘導体
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
UA112795C2 (uk) 2012-03-28 2016-10-25 Мерк Патент Гмбх Біциклічні піразинонові похідні
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
HRP20161033T1 (hr) 2012-05-04 2016-10-21 Merck Patent Gmbh Derivati pirolotriazinona
WO2013177349A2 (en) 2012-05-25 2013-11-28 Glaxosmithkline Llc Quinazolinediones as tankyrase inhibitors
BR112014030410A2 (pt) 2012-06-07 2017-06-27 Hoffmann La Roche inibidores de pirazolopirimidona e pirazolopiridona de tanquirase
RU2014151004A (ru) 2012-06-07 2016-08-10 Ф. Хоффманн-Ля Рош Аг Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
JP2015520205A (ja) 2012-06-20 2015-07-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト タンキラーゼのピロロピラゾン阻害剤
WO2013189904A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Pyranopyridone inhibitors of tankyrase
SG11201500732TA (en) 2012-08-08 2015-02-27 Merck Patent Gmbh (aza-)isoquinolinone derivatives
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
AR092211A1 (es) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung Derivados de hidropirrolopirrol
AU2013324681B2 (en) 2012-09-26 2017-08-10 Merck Patent Gmbh Quinazolinone derivatives as PARP inhibitors
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022235492A1 (en) * 2021-05-04 2022-11-10 Board Of Regents, The University Of Texas System Indanone and tetralone-keto or hydroxyl oximes as cancer therapeutics

Also Published As

Publication number Publication date
CA2865511A1 (en) 2013-09-12
US20150099732A1 (en) 2015-04-09
JP2015512885A (ja) 2015-04-30
DK2822656T3 (en) 2017-01-30
MX346147B (es) 2017-03-09
RU2696572C2 (ru) 2019-08-05
WO2013132253A1 (en) 2013-09-12
IN2014MN01875A (enExample) 2015-07-03
EP2822656B1 (en) 2016-10-19
US9193689B2 (en) 2015-11-24
AU2013229229B2 (en) 2017-10-19
KR20150001734A (ko) 2015-01-06
MX2014010509A (es) 2014-10-14
AU2013229229A1 (en) 2014-09-25
EP2822656A1 (en) 2015-01-14
RU2014138194A (ru) 2016-04-27
CN104302358B (zh) 2017-12-05
KR102104144B1 (ko) 2020-04-23
JP6082409B2 (ja) 2017-02-15
CN104302358A (zh) 2015-01-21

Similar Documents

Publication Publication Date Title
ES2611504T3 (es) Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos
US10358446B2 (en) Bruton's tyrosine kinase inhibitors
US20240182490A1 (en) Bromodomain inhibitors
JP5608655B2 (ja) Ｐ２ｘ３受容体活性のモジュレーター
ES2848978T3 (es) Agentes inmunomoduladores
ES2812626T3 (es) Inhibidores de la desmetilasa 1 específica de lisina
EP3405192B1 (en) Bruton's tyrosine kinase inhibitors
IL272130A (en) Lysine-specific inhibitors of demethylase-1
US10336697B2 (en) Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
EP1828180A1 (en) 1h-pyrrolo[2,3-beta]pyridines
JP2020518669A (ja) 非縮合三環式化合物
JP7440572B2 (ja) デュアルｍａｇｌ及びｆａａｈインヒビター
EP3083631B1 (en) Wnt pathway modulators
JP2021533110A (ja) 癌免疫療法剤としての新規エクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ−１（ＥＮＰＰ１）の置換３Ｈ−イミダゾ［４，５−ｃ］ピリジンおよび１Ｈ−ピロロ［２，３−ｃ］ピリジンシリーズならびにインターフェロン遺伝子刺激因子（ＳＴＩＮＧ）調節剤
AU2014320149A1 (en) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN110494433A (zh) 布鲁顿酪氨酸激酶抑制剂
KR20110133049A (ko) 항암 약물로서의 니코틴아미드 유도체, 그의 제조법 및 그의 치료 용도
CA2506799A1 (en) Mixed lineage kinase modulators
CA2920537C (en) Piperidine urea derivatives as inhibitors of tankyrase
CN113631228A (zh) 作为sting激动剂的大环化合物
IL285074B1 (en) Gpr35 modulators
CA2478310A1 (en) N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors
AU2024240851A1 (en) Triazine compound and use thereof
CN102149706A (zh) 4-氧代-l,4-二氢-喹啉的抗肿瘤的衍生物、其制备方法和其治疗用途
US10793566B2 (en) Bruton's tyrosine kinase inhibitors